메뉴바로가기 본문바로가기

Technology

Improving Human Wellness Through Innovative Recombinant Protein Biotechnology

Technology

Virus-like-Particle (VLP)-Based Recombinant Vaccine Platform

RIPT, an IP-based proprietary technology of InThera*enables high-yield & rapid VLP production through the highly-efficient soluble expression of
target proteins in E. coli, where the yield of VLP formation is low.
In vitro self-assembly enables rapid production of high-quality homogeneous VLPs compared to other VLP production system.

Limitations of producing VLP in insect cells

  • 1 Drawbacks of VLP formation in culture cells

    • - Containing insect cell-derived impurities in particles
    • - Particle heterogeneity

  • 2Difficulty in removing Baculovirus, the vector to
    deliver antigen genes into culture cells

    Low yield & high manufacturing cost

  • 3Expensive cell culture facilities & a long-term manufacturing period

Expected benefits of developing E. coli-produced VLP

  • 1 In vitro self-assembly with purified protein antigens

    • - Antigen purity , Impurities
    • - VLP homogeneity
    Higher efficacy &
    Lower side effects

  • 2Highly-efficient and rapid production in E. coli (within a week)

  • 3Significant reduction in investment and manufacturing costs

Competitiveness of E. coli-produced VLP

  • Rapid response to pandemic outbreak of emerging viral infection

    Pandemic within a few months (e.g., MERS & Zika)

    Development and delivery of customized vaccines in a timely manner

  • Development of multivalent vaccines against new and mutated viruses

    Proper means coping with hyper-variable RNA viruses

  • Overcoming of the limitations in efficacy and safety of conventional vaccines

    High yield production of recombinant antigens with high purity